1Muller A J, Prendergast GC. Indoleamine 2, 3-dioxygenase in immune supp ression and cancer [ J ]. CUlT Cancer Drug Targets, 2007,7( 1 ) :31-40.
2Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance[ J ]. J Clin Invest, 2007,117 (5) : 1147-1154.
3Hiroaki Y, Katsuji T, Rytaro Y, et al. Interferon enhances tryp tophan metabolism by inducing pulmonary indoleamine 2, 3-dioxygenase : Its possible occurrence in cancer patients [ J ]. Proc Nat Acad Sci, 1986,83(9) :6622-6626.
4Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral im2 mune resistancemechanism based on tryp tophan degradation by indoleamine 2, 3-dioxygenase[ J ]. Nat Med, 2003,9 (10) : 1269- 1274.
5Orabona C, Puecetti P, Vacca C, et al. Toward the identification of a tolerogenie signature in IDO2 competent dendritic cells[ J]. Blood, 2006,107( 1 ) :2846-2854.
6Odemuyiwa SO, Ghahary A, Li Y, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2, 3- dioxygenase[J]. J Immunol, 2004, 173(10) :5909-5913.
7Brandacher G, Perathoner A, Ladumer R, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor2infiltrating T cells [ J ]. Clin Cancer Res, 2006,12 (4) :1142-1151.
8Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleaminc 2, 3-dioxygenase [ J ]. Immunity, 2005,22 ( 5 ) : 633- 642.
